Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

2018 Provenge (sipuleucel-T; Sanpower Group) Drug Analysis: A Cellular Immunotherapy Composed of Autologous Dendritic Cells Loaded with the Recombinant Antigen Prostatic Acid Phosphatase -

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Provenge" drug pipelines has been added to's offering.

Drug Overview

Provenge (sipuleucel-T; Sanpower Group) is a cellular immunotherapy composed of autologous dendritic cells loaded with the recombinant antigen prostatic acid phosphatase (PAP), which is expressed on approximately 95% of prostate tumor cells. The vaccine is administered alongside a granulocyte-macrophage colony-stimulating factor adjuvant. Upon injection, the PAP-loaded dendritic cells cause activation of T cells, which recognize the target antigen and destroy prostate tumor cells.

Key Topics Covered:

List of Figures

Figure 1: Provenge for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of Provenge for prostate cancer

Figure 3: Drug assessment summary of Provenge for prostate cancer

Figure 4: Provenge sales for prostate cancer in the US, 2017-26

List of Tables

Table 1: Provenge drug profile

Table 2: Provenge pivotal Phase III data in prostate cancer

Table 3: Provenge sales for prostate cancer in the US ($m), 2017-26

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.